Assessment of the Efficacy and Tolerability of 2 Formulations of Atorvastatin in Korean Adults With Hypercholesterolemia: A Multicenter, Prospective, Open-Label, Randomized Trial

Clinical Therapeutics

Volumn 35, Issue 1, 2013, Pages 77-86

  Kim, Sang Hyun ^a,b   Seo, Myung Ki ^a,c   Yoon, Myeong Ho ^d   Choi, Dong Hoon ^e   Hong, Taek Jong ^f   Kim, Hyo Soo ^a,c  

^a Seoul National University College of Medicine   (South Korea)

^b Seoul National University Boramae Hospital   (South Korea)

^c Seoul National University Hospital   (South Korea)

^d Ajou University Medical Center   (South Korea)

^e Yonsei University College of Medicine   (South Korea)

^f Pusan National University Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ATORVASTATIN; C REACTIVE PROTEIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HIGH SENSITIVITY C REACTIVE PROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CORONARY ARTERY DISEASE; COUGHING; CREATINE KINASE BLOOD LEVEL; DRUG EFFICACY; DRUG FORMULATION; DRUG TOLERABILITY; EDEMA; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; INDIGESTION; KOREA; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MALE; MYALGIA; OPEN STUDY; PARTICLE SIZE; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; SIDE EFFECT; THORAX PAIN; TOXIC HEPATITIS; TREATMENT DURATION;

ADULT; AGED; AGED, 80 AND OVER; APOLIPOPROTEIN A-I; APOLIPOPROTEINS B; ASIAN CONTINENTAL ANCESTRY GROUP; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CHEMISTRY, PHARMACEUTICAL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DRUGS, GENERIC; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PYRROLES; REPUBLIC OF KOREA; THERAPEUTIC EQUIVALENCY; TIME FACTORS; TREATMENT OUTCOME; TRIGLYCERIDES; YOUNG ADULT;

EID: 84872373209     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2012.11.009     Document Type: Article

References (20)

1. Lee S.H., Chung N., Kwan J., et al. Comparison of the efficacy and tolerability of pitavastatin and atorvastatin: an 8-week, multicenter, randomized, open-label, dose-titration study in Korean patients with hypercholesterolemia. Clin Ther 2007, 29:2365-2373.
2. Jones P., Davidson M., Stein E., et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol 2003, 92:152-160. STELLAR Study Group.
3. Shepherd J., Hunninghake D., Barter P., et al. Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals. Am J Cardiol 2003, 91:11-17.
4. Wang K.Y., Ting C.T. A randomized, double-blind, placebo-controlled, 8-week study to evaluate the efficacy and safety of once daily atorvastatin (10 mg) in patients with elevated LDL-cholesterol. Jpn Heart J 2001, 42:725-738.
5. Olsson A., Istad H., Luurila O., et al. Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia. Am Heart J 2002, 144:1044-1051.
6. Bakker-Arkema R., Best J., Fayyad R., et al. A brief review paper of the efficacy and safety of atorvastatin in early clinical trials. Atherosclerosis 1997, 131:17-23.
7. Treasure C.B., Klein J.L., Weintraub W.S., et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995, 332:481-487.
8. Eichstadt H., Eskotter H., Hoffmann I., et al. Improvement of myocardial perfusion by short-term fluvastatin therapy in coronary artery disease. Am J Cardiol 1995, 76:122A-125A.
9. Park S., Kang H., Rim S., et al. A randomized, open-label study to evaluate the efficacy and safety of pitavastatin compared with simvastatin in Korean patients with hypercholesterolemia. Clin Ther 2005, 27:1074-1082.
10. Vaughan C.J., Murphy M.B., Buckley B.M. Statins do more than just lower cholesterol. Lancet 1996, 348:1079-1082.
11. Johnson C., Waters D., DeMicco D., et al. Comparison of effectiveness of atorvastatin 10 mg versus 80 mg in reducing major cardiovascular events and repeat revascularization in patients with previous percutaneous coronary intervention (post hoc analysis of the Treating to New Targets [TNT] Study). Am J Cardiol 2008, 102:1312-1317.
12. Scirica B., Morrow D., Cannon C., et al. Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 study. J Am Coll Cardiol 2006, 47:2326-2331.
13. World Medical Association Declaration of Helsinki: Ethical Principles for medical Research involving Human Subject. Adopted by the 18th WMA General Assembly, Helsinki, Finland, June 1964, and amended by the 52nd WMA General Assembly, Edinburgh, Scotland, October 2000 Accessed December 20, 2012. http://www.wma.net/en/30publications/10policies/b3/.
14. Guideline for Good Clinical Practice. ICH Topic E6 2002, European Agency for the Evaluation of Medical Products, International Conference on Harmonization-World Health Organization, WHO, Geneva, Switzerland, Accessed December 20, 2012. http://apps.who.int/prequal/info_general/documents/GCP/GCP_handbook.pdf.
15. Lipid Standardization Program Centers for Disease Control and Prevention, Department of Health and Human Services, Accessed June 28, 2010. http://www.cdc.gov/labstandards/lsp.htm.
16. International Monitoring of Adverse Reactions to Drugs: Adverse Reaction Terminology 1992, World Health Organization, WHO Collaborating Centre for International Drug Monitoring, Uppsala, Sweden.
17. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001, 285:2486-2497. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults.
18. Ridker P.M. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003, 107:363-369.
19. Ridker P.M., Hennekens C.H., Buring J.E., Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000, 342:836-843.
20. Ridker P.M., Rifai N., Rose L., et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002, 347:1557-1565.